Clinical Trial Search

Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 86 Participants

Primary: Percentage of Participants With Overall Complete Hematologic Response (CHR) — 18.1; 53.3 percentage of participants — p=<0.0001

Primary: Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants — -1.3; -1.8; -1.6 micturitions per…

Primary: Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period — -1.98; -3.60 migraine days / month — p=<0.001

Primary: Change in Global Spontaneous Pain Intensity of Target Hand — -20; -11.3 mm — p=0.016

Primary: Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) — 1.961; 1.089; 2.734 Angioedema event rate per…

Primary: Number of Participants With Adverse Events (AEs) — 32; 70 Participants

Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120

Primary: First Adjudicated Serious Fall-Related Injury — 4.87; 5.34 events per 100 person years of follow-up — p=0.245

Primary: Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) — 1.65; 1.31; 2.35 HAE attack rate per 28…

Primary: Percentage of Subjects With Successful Overall Colon Preparation, Assessed With the Cleansing Score (4-point Scale) — 71.42; 79.03 adjusted percentage of subjects…

Primary: AEs in PD Patients Taking Nabilone, Between V 1 and V 3 — 39 adverse events

Primary: Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal — 269; 23…

Primary: Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup — 9.2; 11.2 months — p=0.113